Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2016 | Research article

Effect of DanQi Pill on PPARα, lipid disorders and arachidonic acid pathway in rat model of coronary heart disease

Authors: Hong Chang, Qiyan Wang, Tianjiao Shi, Kuiyuan Huo, Chun Li, Qian Zhang, Guoli Wang, Yuanyuan Wang, Binghua Tang, Wei Wang, Yong Wang

Published in: BMC Complementary Medicine and Therapies | Issue 1/2016

Abstract

Background

Danqi pill (DQP) is one of the most widely prescribed formulas and has been shown to have remarkable protective effect on coronary heart disease (CHD). However, its regulatory effects on lipid metabolism disorders haven’t been comprehensively studied so far. We aimed to explore the effects of DQP on Peroxisome Proliferator activated receptors α (PPARα), lipid uptake-transportation-metabolism pathway and arachidonic acid (AA)-mediated inflammation pathway in rats with CHD.

Methods

80 Sprague-Dawley (SD) Rats were randomly divided into sham group, model group, positive control group and DQP group. Rat model of CHD was induced by ligation of left ventricle anterior descending artery and fed with high fat diet in all but the sham group. Rats in sham group only underwent thoracotomy. After surgery, rats in the positive control and DQP group received daily treatments of pravastatin and DQP respectively. At 28 days after surgery, rats were sacrificed and plasma lipids were evaluated by plasma biochemical detection. Western blot and PCR were applied to evaluate the expressions of PPARα, proteins involved in lipid metabolism and AA pathways.

Results

Twenty eight days after surgery, dyslipidemia developed in CHD model rats, as illustrated by elevated plasma lipid levels. Expressions of apolipoprotein A-I (ApoA-I), cluster of differentiation 36 (CD36) and fatty acid binding protein (FABP) in the heart tissues of model group were down-regulated compared with those in sham group. Expressions of carnitine palmitoyl transferase I (CPT-1A) and lipoproteinlipase (LPL) were also reduced significantly. In addition, levels of phospholipase A2 (PLA2) and cyclooxygenase 2 (COX-2) were up-regulated. Expressions of Nuclear factor-κB (NF- κB) and signal transducer and activator of transcription 3 (STAT3) also increased. Furthermore, Expression of PPARα decreased in the model group. DQP significantly up-regulated expressions of ApoA-I and FABP, as well as the expressions of CPT-1A and CD36. In addition, DQP down-regulated expressions of PLA2, COX-2 and NF-κB in inflammation pathway. Levels of STAT3 and LPL were not affected by DQP treatment. In particular, DQP up-regulated PPARα level significantly.

Conclusions

DQP could effectively regulate lipid uptake-transportation-metabolism process in CHD model rats, and the effect is achieved mainly by activating ApoA-I-CD36-CPT-1A molecules. Interestingly, DQP can up-regulate expression of PPARα significantly. The anti-inflammatory effect of DQP is partly exerted by inhibiting expressions of PLA2-COX2 -NF-κB pathway.

DiNicolantonio JJ, Lucan SC, O’Keefe JH. The evidence for saturated fat and for sugar related to coronary heart disease. Prog Cardiovasc Dis. 2015.

Wu T, Sun QF, Yang PS, Feng W, Liu XL. [Levels of inflammation cytokines in patients with coronary heart disease and periodontal disease]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2010;45(5):265–8.PubMed

Ma Y, Ockene IS, Rosal MC, Merriam PA, Ockene JK, Gandhi PJ. Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol. 2010;2010:383281.CrossRefPubMedPubMedCentral

Rosen VM, Taylor DC, Parekh H, Pandya A, Thompson D, Kuznik A, Waters DD, Drummond M, Weinstein MC. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US. Pharmacoeconomics. 2010;28(1):47–60.CrossRefPubMed

Bittner V, Deng L, Rosenson RS, Taylor B, Glasser SP, Kent ST, Farkouh ME, Muntner P. Trends in the use of nonstatin lipid-lowering therapy among patients with coronary heart disease: a retrospective cohort study in the medicare population 2007 to 2011. J Am Coll Cardiol. 2015;66(17):1864–72.CrossRefPubMed

Dargel R. The lipid infiltration theory of atherosclerosis. Z Med Lab Diagn. 1989;30(5):251–5.PubMed

Graham I, Cooney MT, Bradley D, Dudina A, Reiner Z. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep. 2012;14(6):709–20.CrossRefPubMed

Barter P. HDL: a recipe for longevity. Atheroscler Suppl. 2004;5(2):25–31.CrossRefPubMed

Mulay V, Wood P, Rentero C, Enrich C, Grewal T. Signal transduction pathways provide opportunities to enhance HDL and apoAI-dependent reverse cholesterol transport. Curr Pharm Biotechnol. 2012;13(2):352–64.CrossRefPubMed

10.

Tuunanen H, Ukkonen H, Knuuti J. Myocardial fatty acid metabolism and cardiac performance in heart failure. Curr Cardiol Rep. 2008;10(2):142–8.CrossRefPubMed

11.

Cook GA, Edwards TL, Jansen MS, Bahouth SW, Wilcox HG, Park EA. Differential regulation of carnitine palmitoyltransferase-I gene isoforms (CPT-I alpha and CPT-I beta) in the rat heart. J Mol Cell Cardiol. 2001;33(2):317–29.CrossRefPubMed

12.

Mengi SA, Dhalla NS. Carnitine palmitoyltransferase-I, a new target for the treatment of heart failure: perspectives on a shift in myocardial metabolism as a therapeutic intervention. Am J Cardiovasc Drugs. 2004;4(4):201–9.CrossRefPubMed

13.

Wang Y, Li C, Wang Q, Shi T, Wang J, Chen H, Wu Y, Han J, Guo S, Wang W. Danqi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway. BMC Complement Altern Med. 2015;15:28.CrossRefPubMedPubMedCentral

14.

Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86(5):580–8.CrossRefPubMed

15.

Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. Inflammation in myocardial diseases. Circ Res. 2012;110(1):126-44.

16.

Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol. 2004;5(9):241.CrossRefPubMedPubMedCentral

17.

Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res. 2001;480–481:243–68.CrossRefPubMed

18.

LaPointe MC, Mendez M, Leung A, Tao ZY, Yang XP. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol-Heart C. 2004;286(4):H1416–24.CrossRef

19.

Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360(9339):1071–3.CrossRefPubMed

20.

Robinson E, Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther. 2009;122(3):246–63.CrossRefPubMed

21.

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.CrossRefPubMed

22.

Rakhshandehroo M, Knoch B, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010;2010.

23.

Bocher V, Chinetti G, Fruchart JC, Staels B. [Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control]. J Soc Biol. 2002;196(1):47–52.PubMed

24.

Wilson JL, Duan R, El-Marakby A, Alhashim A, Lee DL. Peroxisome Proliferator Activated Receptor-alpha Agonist Slows the Progression of Hypertension, Attenuates Plasma Interleukin-6 Levels and Renal Inflammatory Markers in Angiotensin II Infused Mice. PPAR Res. 2012;2012:645969.CrossRefPubMedPubMedCentral

25.

Wang Y, Li C, Liu Z, Shi T, Wang Q, Li D, Wu Y, Han J, Guo S, Tang B, et al. DanQi Pill protects against heart failure through the arachidonic acid metabolism pathway by attenuating different cyclooxygenases and leukotrienes B4. BMC Complement Altern Med. 2014;14:67.CrossRefPubMedPubMedCentral

26.

Chen J, Wang F, Lee FS, Wang X, Xie M. Separation and identification of water-soluble salvianolic acids from Salvia miltiorrhiza Bunge by high-speed counter-current chromatography and ESI-MS analysis. Talanta. 2006;69(1):172–9.CrossRefPubMed

27.

Wan JB, Lai CM, Li SP, Lee MY, Kong LY, Wang YT. Simultaneous determination of nine saponins from Panax notoginseng using HPLC and pressurized liquid extraction. J Pharm Biomed Anal. 2006;41(1):274–9.CrossRefPubMed

28.

Ministry of Health of the People’s Republic of China Pharmacopoeia Committee. China pharmaceutical standards for formulations and the drug prescription of the ministry of health of the People’s Republic. Chin Med Sci Technol Press. 2010;1:107–16.

29.

Chen S, Liu J, Liu X, Fu Y, Zhang M, Lin Q, Zhu J, Mai L, Shan Z, Yu X, et al. Panax notoginseng saponins inhibit ischemia-induced apoptosis by activating PI3K/Akt pathway in cardiomyocytes. J Ethnopharmacol. 2011;137(1):263–70.CrossRefPubMed

30.

Tu EY, Zhou YG, Wang ZH, Liang QS, Yang GT. Effects of tanshinone II A on the myocardial hypertrophy signal transduction system protein kinase B in rats. Chin J Integr Med. 2009;15(5):365–70.CrossRefPubMed

31.

Wang Y, Li C, Ouyang YL, Chuo WJ, Yu JD, Han J, Chen JX, Wang W. The study on therapy effect of Danqi pill to renin-angiotensin-aldosterone system (RAAS) and lipid metabolism disorder in coronary heart disease. Afr J Pharm Pharmaco. 2012;6(35):2607–12.CrossRef

32.

Wang Y, Li C, Wang QY, Shi TJ, Wang J, Chen H, Wu Y, Han J, Guo SZ, Wang YY, et al. Danqi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway. Bmc Complem Altern M. 2015;15.

33.

Shang QH, Liu ZL, Chen KJ, Xu H, Liu JP. A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evid-Based Compl Alt. 2012;2012:636547.

34.

Gao ZY, Xu H, Shi DZ, Wen C, Liu BY. Analysis on outcome of 5284 patients with coronary artery disease: The role of integrative medicine. J Ethnopharmacol. 2012;141(2):578–83.CrossRefPubMed

35.

Rana JS, Visser ME, Arsenault BJ, Despres JP, Stroes ES, Kastelein JJ, Wareham NJ, Boekholdt SM, Khaw KT. Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Int J Cardiol. 2010;143(3):399–404.CrossRefPubMed

36.

Majeed F, Miller M. Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment. Curr Opin Endocrinol Diabetes Obes. 2008;15(2):175–81.CrossRefPubMed

37.

Greene DJ, Skeggs JW, Morton RE. Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J Biol Chem. 2001;276(7):4804–11.CrossRefPubMed

38.

Skeggs JW, Morton RE. LDL and HDL enriched in triglyceride promote abnormal cholesterol transport. J Lipid Res. 2002;43(8):1264–74.PubMed

39.

Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C, Sacks FM. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;106(6):757–63.CrossRefPubMedPubMedCentral

40.

Cui Y, Watson DJ, Girman CJ, Shapiro DR, Gotto AM, Hiserote P, Clearfield MB. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). Am J Cardiol. 2009;104(6):829–34.CrossRefPubMed

41.

Ibanez B, Vilahur G, Cimmino G, Speidl WS, Pinero A, Choi BG, Zafar MU, Santos-Gallego CG, Krause B, Badimon L, et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol. 2008;51(11):1104–9.CrossRefPubMed

42.

Nicholls SJ, Gordon A, Johannson J, Ballantyne CM, Barter PJ, Brewer HB, Kastelein JJP, Wong NC, Borgman MRN, Nissen SE. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drug Ther. 2012;26(2):181–7.CrossRef

43.

Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density-lipoproteins inhibit cytokine-induced expression of endothelial-cell adhesion molecules. Arterioscl Throm Vas. 1995;15(11):1987–94.CrossRef

44.

Berk PD. Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. Hepatology. 2008;48(5):1362–76.CrossRefPubMedPubMedCentral

45.

Luiken JJFP, Koonen DPY, Willems J, Zorzano A, Becker C, Fischer Y, Tandon NN, van der Vusse GJ, Bonen A, Glatz JFC. Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes. 2002;51(10):3113–9.CrossRefPubMed

46.

Tanaka T, Nakata T, Oka T, Ogawa T, Okamoto F, Kusaka Y, Sohmiya K, Shimamoto K, Itakura K. Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutations. J Lipid Res. 2001;42(5):751–9.PubMed

47.

Smith BK, Jain SS, Rimbaud S, Dam A, Quadrilatero J, Ventura-Clapier R, Bonen A, Holloway GP. FAT/CD36 is located on the outer mitochondrial membrane, upstream of long-chain acyl-CoA synthetase, and regulates palmitate oxidation. Biochem J. 2011;437:125–34.CrossRefPubMed

48.

He JH, Lee JH, Febbraio M, Xie W. The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Exp Biol Med. 2011;236(10):1116–21.CrossRef

49.

Bruce CR, Hoy AJ, Turner N, Watt MJ, Allen TL, Carpenter K, Cooney GJ, Febbraio MA, Kraegen EW. Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance. Diabetes. 2009;58(3):550–8.CrossRefPubMedPubMedCentral

50.

Levick SP, Loch DC, Taylor SM, Janicki JS. Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol. 2007;178(2):641–6.CrossRefPubMed

51.

Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation. 2002;106(2):167–9.CrossRefPubMed

52.

Issemann I, Prince RA, Tugwood JD, Green S. The peroxisome proliferator-activated receptor retinoid-x receptor heterodimer is activated by fatty-acids and fibrate hypolipemic drugs. J Mol Endocrinol. 1993;11(1):37–47.CrossRefPubMed

53.

Auwerx J, Schoonjans K, Fruchart JC, Staels B. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis. 1996;124:S29–37.CrossRefPubMed

54.

Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37(5):907–25.PubMed

55.

Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPAR alpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis. 2009;205(1):1–8.CrossRefPubMed

56.

Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui JQ, Thudium DT, Boyce R, Burns-Kurtis CL, et al. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation. 2003;108(19):2393–9.CrossRefPubMed

57.

Shonde A, Bennett A, Hawkey CJ. Suppression of cyclooxygenase (COX)-2 and cellular proliferation in colonocytes by indornethacin: role of leukotriene (LT)B4, a (Ppar)alpha ligand. Gastroenterology. 2007;132(4):A427.

Title: Effect of DanQi Pill on PPARα, lipid disorders and arachidonic acid pathway in rat model of coronary heart disease
Authors: Hong Chang
Qiyan Wang
Tianjiao Shi
Kuiyuan Huo
Chun Li
Qian Zhang
Guoli Wang
Yuanyuan Wang
Binghua Tang
Wei Wang
Yong Wang
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Complementary Medicine and Therapies / Issue 1/2016
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-016-1083-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Effect of DanQi Pill on PPARα, lipid disorders and arachidonic acid pathway in rat model of coronary heart disease

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

RETRACTED ARTICLE: A candidate Chinese medicine preparation-Fructus Viticis Total Flavonoids inhibits stem-like characteristics of lung cancer stem-like cells

Usage of Plant Food Supplements (PFS) for weight control in six European countries: results from the PlantLIBRA PFS Consumer Survey 2011-2012

Evaluation of Salvadora persica L. and green tea anti-plaque effect: a randomized controlled crossover clinical trial

Effect of Radix Stemonae concentrated decoction on the lung tissue pathology and inflammatory mediators in COPD rats

Effectiveness and safety of ShenXiong glucose injection for acute ischemic stroke: a systematic review and GRADE approach

Evaluation of Hepatoprotective activity of Eriocaulon quinquangulare in vitro using porcine liver slices against ethanol induced liver toxicity and free radical scavenging capacity